Compare WVE & HP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | HP |
|---|---|---|
| Founded | 2012 | 1920 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | 2015 | N/A |
| Metric | WVE | HP |
|---|---|---|
| Price | $15.74 | $30.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $29.94 | $29.09 |
| AVG Volume (30 Days) | ★ 13.7M | 1.3M |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.34% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $109,230,000.00 | ★ $3,746,013,000.00 |
| Revenue This Year | N/A | $9.18 |
| Revenue Next Year | $16.00 | $3.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 103.75 | 35.89 |
| 52 Week Low | $5.28 | $14.65 |
| 52 Week High | $21.73 | $37.30 |
| Indicator | WVE | HP |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 62.59 |
| Support Level | $15.23 | $27.54 |
| Resistance Level | $18.50 | $29.23 |
| Average True Range (ATR) | 1.18 | 1.00 |
| MACD | -0.34 | -0.00 |
| Stochastic Oscillator | 16.51 | 87.38 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.